Navigation Links
MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
Date:11/20/2012

SAN DIEGO, Nov. 20, 2012 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of proprietary immunotherapies to address the unmet medical need of preventing recurrent cancer, today announced the closing of the first tranche in their Series B financing.  Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million. The additional capital will allow MabVax to continue the development of its phase 2 vaccine aimed at preventing recurrent sarcoma and its 5B1 antibody program targeting metastatic pancreatic cancer.

The phase 2 clinical trial of the sarcoma vaccine has reached the targeted enrollment of 134 stage IV sarcoma patients in a randomized, multicenter, double-blind study of a vaccine specifically developed to elicit a targeted antibody response intended to kill residual circulating cancer cells and micrometastases that can cause recurrent sarcoma. The primary efficacy result of progression free survival (PFS) is expected to be reported in the second half of 2013.  The financing provides MabVax access to Numoda's advanced and patented clinical trial information technologies and management systems. These technologies will enable MabVax to move through the clinical trial process efficiently while providing visibility for reporting early assessments and timely trial results.  

The financing will also allow MabVax to continue development of the 5B1 antibody program targeting an antigen that is widely expressed in pancreatic cancer. The company has discovered and completed preclinical testing of a fully human IgG1 antibody with high affinity and exquisite specificity for the antigen and remarkable in vivo efficacy in a series of pancreatic and other cancer cell lines in SCID mice. MabVax is planning to begin GMP manufacturing of this antibody early in 2013
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
2. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
3. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
4. Echo Therapeutics Chosen to Present at the 12th Annual Diabetes Technology Meeting
5. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
6. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
7. Echo Therapeutics Announces Third Quarter 2012 Financial Results
8. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
9. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
10. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Novelos Therapeutics Closes $2 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 /PRNewswire/ ... VRX ) (TSX: VRX) ... directors nominated at its 2013 annual ... results of the vote for the ... below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo ...
(Date:5/21/2013)... Massachusetts , 21. Mai 2013 /PRNewswire/ ... („OSI"), die die Firmen OMNIlife science® Inc., Enztec ... zählt, hat zwei neue, erfahrene Mitglieder in ... , eine erfahrene Führungspersönlichkeit aus der ... David Johnson , anerkannter ...
(Date:5/21/2013)... , 21 de mayo de 2013 La ... compañías filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y ... para su junta. Guy Mayer, un ejecutivo ortopédico experimentado, ... David Johnson , un experto refutado ... Antes de unirse a OSI como presidente ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3
... improvement solutions provider GP Strategies Corporation (NYSE: ... ended March 31, 2012. Overview of First Quarter ... quarter of 2012 compared to $64.3 million for first quarter of ... of 2012 compared to $4.3 million for first quarter of 2011 ...
... 2012 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant has agreed to acquire certain assets ... company focused on skincare products, for approximately $64 ... future revenue targets.  University Medical,s main brand is ...
Cached Medicine Technology:GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 2GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 3GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 4GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 5GP Strategies Reports Strong First Quarter 2012 EPS of $0.23 6Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical 2
(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... MedMar Healing Center announces their participation in ... Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and clubs, ... goal is to raise food to help area kids who ... in recent years. , “We like being able to ... explains Douglas Chloupek of MedMar Healing Center. “Taking part in ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
(Date:5/21/2013)... 2013 The nation’s first trial involving ... nearing its conclusion in Washington state court, Bernstein Liebhard ... yesterday, an attorney for the Plaintiffs compared Intuitive Surgical ... tie sales and services for its customers. ... control of surgeons, to keep control of hospitals and ...
(Date:5/21/2013)... May 21, 2013 Two executives from ... (SBG) will identify which strategies can be most effective ... care to the members who are taking them, in ... Inc., “How to Manage Specialty Drugs to Reduce ... are now the main driver for rising prescription drug ...
Breaking Medicine News(10 mins):Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2
... MONICA, Calif., Dec. 7 California,s,stem cell agency ... it was,rejecting 10 applications for research grants because ... billion stem cell program, the,Foundation for Taxpayer and ... consumer advocacy organization added that,to completely resolve the ...
... Dec. 7 Legendary blues artists Bobby,Rush and James ... the inaugural Mississippi Blues Marathon and Half-Marathon on Saturday,January ... & Mal,s, located at 200,South Commerce Street, in downtown ... scheduled to go on stage at 8:00 p.m., and ...
... for four blood proteins may provide a less-invasive follow-up for ... tomography (CT) scans, according to a new study led by ... a very high false positive rate when trying to discover ... Duke and lead investigator on the study. What that leads ...
... BioHorizons Implant Systems,Inc. relocated its global ... 44,000 square foot facility. The new facility, ... services, a newly,formed manufacturing facility and a ... surface treatment and packaging services., The ...
... 7 As of December 7,2007, Coshocton County Memorial ... nurses for a 3-year contract. As a result,bargaining unit ... strike,and maintain a picket line starting at 7:00 a.m. ... highly developed skills and extensive,education. Each and every day ...
... BAN(R)/Seventeen.com Stress Relief Survey are in, NEW YORK, Dec. ... and messy breakups anymore. The fast-paced world we live in ... people, especially young,women, face. This trend can be seen in ... what are some of the factors that contribute,to this new ...
Cached Medicine News:Health News:Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say 2Health News:Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say 3Health News:Study points to possibility of blood test to detect lung cancer 2Health News:BioHorizons Expands to New 44,000 Square Foot Facility 2Health News:Coshocton County Memorial Hospital RNs to Strike Despite Hospital's Claim of Financial Hardship 2Health News:Coshocton County Memorial Hospital RNs to Strike Despite Hospital's Claim of Financial Hardship 3Health News:What Stresses Teens Out 2Health News:What Stresses Teens Out 3
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... Liquichek Lipids Control is ... product that provides the ... analyte levels for lipids ... C-Reactive Protein in levels ...
... Control (Human) provides a comprehensive analyte ... and CO2. It requires no special ... major instruments and methodologies. Available in ... sizes (10 mL fill size available ...
Medicine Products: